STEPHANIE CRAWFORD: Open Payments
NPI 1265081616 · MIDLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$640 in 37 payments from 9 companies in 2025. Trend: 2023 $482 · 2024 $615 · 2025 $640
Food & beverage: $640
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $236 |
| E.R. Squibb & Sons, L.L.C. | 13 | $136 |
| Actelion Pharmaceuticals US, Inc. | 3 | $60 |
| Medtronic, Inc. | 2 | $56 |
| Novo Nordisk Inc | 2 | $35 |
| Amgen Inc. | 2 | $34 |
| PFIZER INC. | 2 | $32 |
| Boston Scientific Corporation | 1 | $26 |
| Merck Sharp & Dohme LLC | 1 | $25 |
Products named: FARXIGA, CAMZYOS, WAINUA, ELIQUIS, COREVALVE EVOLUT R, OPSYNVI, Wegovy, REPATHA.
Industry payments across TX — which companies pay providers there.
